ARCHIVES

In Brief: Litton Bionetic’s New contract For Operation of FCRC Total $128.8 Million For Five Years

This article is from The Cancer Letter archive.

Vol. 03 No. 40 | October 7, 1977

Download PDF Visit The Full Archive

Related Articles

Sorafenib Targets AML Driven By Mutant FLT3 Gene

February 29, 2008

FDA Approves SNDA For Gardasil For Anal Cancer And Precancerous Lesions

January 28, 2011

DCCP Board Okays Noncompetitive Procurements

June 11, 1982

Milken Calls For Renewed War On Cancer, $20 Billion A Year International Effort

November 24, 1995

In Brief: Louise Strong Named President, AACR; Donald Coffey Is President-Elect

April 26, 1996

Lilly Suspends Phase III Trial Of Tasisulam in Melanoma

January 28, 2011